查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
美國臨床試驗市場規模、份額和趨勢分析報告：按階段（I、II、III、IV 期）、臨床試驗設計（介入試驗、觀察試驗、擴大試驗）、適應症、分部預測，2022- 2030年
市場調查報告書
商品編碼
1170933

美國臨床試驗市場規模、份額和趨勢分析報告：按階段（I、II、III、IV 期）、臨床試驗設計（介入試驗、觀察試驗、擴大試驗）、適應症、分部預測，2022- 2030年

U.S. Clinical Trials Market Size, Share & Trends Analysis Report By Phase (Phase I, II, III, IV), By Study Design (Interventional Trials, Observational Trials, Expanded Access Trials), By Indication, And Segment Forecasts, 2022 - 2030
出版日期: | 出版商: Grand View Research | 英文 204 Pages | 商品交期: 2-10個工作天內

價格

美國臨床試驗市場的增長和趨勢

根據 Grand View Research, Inc. 的最新報告，美國臨床試驗市場預計到 2030 年將達到 363 億美元。從 2022 年到 2030 年，該市場預計將以 5.4% 的複合年增長率增長。美國慢性病患病率上升和對臨床試驗的需求不斷增長正在推動市場增長。

預計在未來八年內，被診斷患有癌症的人數將增加數倍。儘管腫瘤學領域的研究大大提高了生存率，但預計全球癌症患者的數量仍將增加。胰腺癌預後較差，據說生存期為1至3年。每天約有 13 人被診斷出患有胃腸道間質瘤。美國每年有 60,000 多例新病例被診斷出腎細胞癌，癌症發病率的增加增加了對多種癌症有效治療的需求。預計美國的疾病流行將增加研發投資，促進行業增長。

COVID-19 大流行已經停止了新的研究項目，並改變了對其他疾病的資源分配。臨床試驗樣本的供應鏈也因邊境關閉而中斷。所以市場動盪不安。然而，COVID-19 的反應正在推動市場上的新領域，這些領域正在改變臨床試驗的實施方式。分佈式/虛擬臨床試驗就是這樣一種技術。虛擬臨床試驗在當前的 COVID-19 情景中發揮著關鍵作用。由於虛擬訪問和遠程患者監控，參與者獲得了選擇和保證，以最大限度地降低風險。監控小工具、軟件工具和手機讓參與者可以在家中完成他們的實驗。

美國臨床試驗市場報告要點

III 期在 2021 年以 53.6% 的銷售份額佔據市場主導地位。這些試驗更為重要，因為它們涉及 300 至 3000 名參與者並且持續時間更長。因此最昂貴的階段

2021年介入板塊佔比最大，46.0%

根據適應症，腫瘤科預計在分析期間的複合年增長率最高，為 5.7%。這種增長歸因於癌症病例數量的增加。因此，大量資金用於腫瘤學臨床試驗。

目錄

第一章 調查方法和範圍

  • 市場細分和範圍
    • 步
    • 臨床試驗設計
    • 展示
  • 調查方法
  • 信息採購
    • 購買的數據庫
    • GVR 內部數據庫
    • 次要信息
    • 初步調查
    • 初步調查詳情
  • 信息或數據分析
    • 數據分析模型
  • 市場製定和驗證
  • 型號詳情
    • 商品流向分析（模型一）
    • 量價分析（模型二）
  • 二級信息列表
  • 主要信息列表
  • 縮略語表
  • 目的

第二章執行摘要

  • 市場展望
  • 分部展望
  • 競爭考慮

3 美國臨床試驗市場：變量、趨勢和範圍

  • 市場系列展望
    • 母公司的市場前景
    • 輔助市場展望
  • 繪製滲透率和增長前景
  • 按 COVID-19 階段劃分的產品管道分析
    • 開發中的療法：271
    • 開發中的疫苗：106
  • 臨床試驗的快速跟蹤
    • FDA 倡議 - CTAP
      • 加速 COVID-19 治療干預和疫苗研發
  • 合作臨床試驗
    • 參與協作臨床試驗
    • 疫苗的協同臨床試驗
  • 虛擬臨床試驗
    • 家庭保健服務：
  • COVID-19 大流行對臨床試驗活動的影響
    • 暫停臨床試驗：
    • 臨床試驗的障礙：
  • 市場動態
    • 市場驅動力分析
      • 在臨床研究中採用新技術
      • 轉向個性化醫療
      • 疾病變異和患病率增加
      • 加強生物醫學研究合作
      • CRO市場的增長
    • 市場約束因素分析
      • 價格壓力
    • 行業挑戰
      • 臨床試驗成本上升
  • 美國臨床試驗市場分析工具
    • 波特五力分析
    • PESTEL 分析
    • 重大交易及戰略聯盟分析
      • 合作
      • 擴張
      • 合夥
      • 獲得
      • 產品發布會
      • 合併
      • 合資企業

第四章美國臨床試驗市場：階段分析

  • 美國臨床試驗：2021 年和 2030 年市場份額分析
  • 第一階段
  • 第二階段
  • 第三階段
  • 第四階段

5美國臨床試驗市場：臨床試驗設計的分段分析

  • 美國臨床試驗：2021 年和 2030 年市場份額分析
  • 干預試驗
  • 觀察測試
  • 擴展訪問測試

6 美國臨床試驗市場：適應症細分分析

  • 美國臨床試驗：2021 年和 2030 年市場份額分析
  • 自身免疫/炎症
    • 類風濕關節炎
    • 多發性硬化症 (MS)
    • 骨關節炎
    • 腸易激綜合症 (IBS)
    • 其他
  • 疼痛管理
    • 慢性疼痛
    • 急性疼痛
  • 腫瘤學
    • 血癌
    • 實體瘤
    • 其他
  • 中樞神經系統狀況
    • 癲癇
    • 帕金森病 (PD)
    • 亨廷頓氏病
    • 中風
    • 創傷性腦損傷 (TBI)
    • 肌萎縮側索硬化症 (ALS)
    • 肌肉再生
    • 其他
  • 糖尿病
  • 肥胖
  • 心血管
  • 其他適應症

7 項美國臨床試驗：適應症展望，通過臨床試驗設計，通過交叉分析

  • 自身免疫/炎症：美國臨床試驗市場，按臨床試驗設計，2018-2030（百萬美元）
    • 干預試驗
    • 觀察測試
    • 擴展訪問測試
  • 疼痛管理：美國臨床試驗市場，按臨床試驗設計，2018-2030 年（百萬美元）
    • 干預試驗
    • 觀察測試
    • 擴展訪問測試
  • 腫瘤學：美國臨床試驗市場，按臨床試驗設計，2018-2030 年（百萬美元）
    • 干預試驗
    • 觀察測試
    • 擴展訪問測試
  • CNS 狀態：美國臨床試驗市場，按臨床試驗設計，2018-2030（百萬美元）
    • 干預試驗
    • 觀察測試
    • 擴展訪問測試
  • 糖尿病：美國臨床試驗市場，按試驗設計，2018-2030 年（百萬美元）
    • 干預試驗
    • 觀察測試
    • 擴展訪問測試
  • 按臨床試驗設計劃分的美國肥胖臨床試驗市場，2018-2030 年（百萬美元）
    • 干預試驗
    • 觀察測試
    • 擴展訪問測試
  • 心血管：美國臨床試驗市場，按臨床試驗設計，2018-2030（百萬美元）
    • 干預試驗
    • 觀察測試
    • 擴展訪問測試
  • 其他：美國臨床試驗市場，按臨床試驗設計，2018-2030（百萬美元）
    • 干預試驗
    • 觀察測試
    • 擴展訪問測試

第八章公司簡介

  • 公司簡介
    • IQVIA Holdings Inc.
      • 公司簡介
      • 財務績效
      • 服務基準
      • 戰略舉措
    • PAREXEL International Corporation
      • 公司簡介
      • 服務基準
      • 戰略舉措
    • Thermo Fisher Scientific（Pharmaceutical Product Development）
      • 公司簡介
      • 服務基準
      • 戰略舉措
    • Charles River Laboratory
      • 公司簡介
      • 財務績效
      • 服務基準
      • 戰略舉措
    • ICON plc
      • 公司簡介
      • 財務績效
      • 服務基準
      • 戰略舉措
    • LabCorp
      • 公司簡介
      • 財務績效
      • 服務基準
      • 戰略舉措
    • Syneos Health Inc.
      • 公司簡介
      • 財務績效
      • 服務基準
      • 戰略舉措
    • SGS SA
      • 公司簡介
      • 財務績效
      • 服務基準
      • 戰略舉措
    • Wuxi AppTec
      • 公司簡介
      • 財務績效
      • 服務基準
      • 戰略舉措
    • Eli Lilly and Company
      • 公司簡介
      • 財務績效
      • 服務基準
    • Novo Nordisk A/S
      • 公司簡介
      • 財務績效
      • 服務基準
    • Pfizer Inc.
      • 公司簡介
      • 財務績效
      • 服務基準
      • 戰略舉措
    • Covance Inc.
      • 公司簡介
      • 財務績效
      • 服務基準
Product Code: GVR-4-68039-580-4

U.S. Clinical Trials Market Growth & Trends:

The U.S. clinical trials market size is expected to reach USD 36.3 billion by 2030, according to a new report by Grand View Research, Inc. The market is anticipated to expand at a CAGR of 5.4% from 2022 to 2030. The increasing prevalence of chronic disease and growing demand for clinical trials in the U.S. is boosting the growth of the market.

The number of people diagnosed with cancer is expected to increase multi-fold in the coming eight years. Although survivors have increased considerably owing to research in the oncology field, the number of cancer patients is expected to increase across the world. Pancreatic cancer has a poor prognosis with a survival of only 1 to 3 years. Approximately 13 people are diagnosed with GI stromal tumors each day. More than 60, 000 new cases of renal cell carcinoma are diagnosed every year in the U.S. Hence, representing an increasing prevalence of cancer and the need for effective treatments against various types of cancer. Investment in R&D is expected to grow owing to the disease prevalence across the U.S. thereby boosting the industry's growth.

The COVID-19 pandemic has halted new research projects and reallocated resources for other diseases. The supply chain for clinical trial samples has also been interrupted as a result of blocked borders. Hence, this market is disrupted. However, the COVID-19 response has resulted in new developments on the market that have transformed the conduct of clinical trials. Decentralized/virtual clinical trials are one such technique. Virtual trials have a very important role in the current COVID-19 scenario. As a result of the virtual visit and remote patient monitoring, participants have a choice and peace of mind to minimize risks. Monitoring gadgets, software tools, and mobile phones enable participants to complete the experiment from their homes.

U.S. Clinical Trials Market Report Highlights:

  • Phase III dominated the market with a revenue share of 53.6% in 2021. These trials are more crucial as they involve 300 to 3000 participants and have a longer period of time. Thus, it is the most expensive phase
  • The interventional segment accounted for the largest share of 46.0% in 2021
  • Based on indication, the oncology segment is anticipated to exhibit the highest CAGR of 5.7% over the analysis timeframe. This growth is due to the growing number of cases of cancer. Thus, a large amount of expenditure is spent on oncology clinical trials

Table of Contents

Chapter 1 Methodology and Scope

  • 1.1 Market Segmentation & Scope
    • 1.1.1 Phase
    • 1.1.2 Study Design
    • 1.1.3 Indication
    • 1.1.4 Estimates And Forecast Timeline
  • 1.2 Research Methodology
  • 1.3 Information Procurement
    • 1.3.1 Purchased Database
    • 1.3.2 GVR's Internal Database
    • 1.3.3 Secondary Sources
    • 1.3.4 Primary Research
    • 1.3.5 Details Of Primary Research
  • 1.4 Information Or Data Analysis
    • 1.4.1 Data Analysis Models
  • 1.5 Market Formulation & Validation
  • 1.6 Model Details
    • 1.6.1 Commodity Flow Analysis (Model 1)
    • 1.6.2 Volume Price Analysis (Model 2)
  • 1.7 List Of Secondary Sources
  • 1.8 List Of Primary Sources
  • 1.9 List Of Abbreviations
  • 1.10 Objectives
    • 1.10.1 Objective - 1:
    • 1.10.2 Objective - 2:
    • 1.10.3 Objective - 3:
    • 1.10.4 Objective - 4:

Chapter 2 Executive Summary

  • 2.1 Market Outlook
  • 2.2 Segment Outlook
  • 2.3 Competitive Insights

Chapter 3 U.S. Clinical Trials Market: Variables, Trends, & Scope

  • 3.1 Market Lineage Outlook
    • 3.1.1 Parent market outlook
    • 3.1.2 Ancillary market outlook
  • 3.2 Penetration & Growth Prospect Mapping
  • 3.3 Product Pipeline Analysis, by Stage for COVID-19
    • 3.3.1 Therapeutics in development: 271
    • 3.3.2 Vaccines in development: 106
  • 3.4 Fast track of clinical trials
    • 3.4.1 FDA initiative- CTAP
      • 3.4.1.1 Accelerating COVID-19 Therapeutic Interventions and Vaccines
  • 3.5 Solidarity clinical trial
    • 3.5.1 Participation in solidarity trials
    • 3.5.2 Solidarity clinical trial for vaccines
  • 3.6 Virtual clinical trials
    • 3.6.1 In-home clinical services:
  • 3.7 COVID-19 pandemic impact on clinical trial activity
    • 3.7.1 Disrupted clinical trials:
    • 3.7.2 Obstacles in clinical trials:
  • 3.8 Market Dynamics
    • 3.8.1 Market Driver Analysis
      • 3.8.1.1 Adoption of new technology in clinical research
      • 3.8.1.2 Shift towards personalized medicine
      • 3.8.1.3 Growing disease variation and prevalence
      • 3.8.1.4 Increasing collaboration in biomedical research
      • 3.8.1.5 Growth in CRO market
    • 3.8.2 Market Restraint Analysis
      • 3.8.2.1 Pricing pressure
    • 3.8.3 Industry Challenges
      • 3.8.3.1 Rising cost of clinical trial
  • 3.9 U.S. Clinical Trials Market Analysis Tools
    • 3.9.1 Porter's Five Forces Analysis
    • 3.9.2 PESTEL Analysis
    • 3.9.3 Major Deals & Strategic Alliances Analysis
      • 3.9.3.1 Collaboration
      • 3.9.3.2 Expansion
      • 3.9.3.3 Partnership
      • 3.9.3.4 Acquisition
      • 3.9.3.5 Product launch
      • 3.9.3.6 Merger
      • 3.9.3.7 Joint venture

Chapter 4 U.S. Clinical Trials Market: Phase Segment Analysis

  • 4.1 U.S. Clinical Trials: Market Share Analysis, 2021 & 2030
  • 4.2 Phase I
    • 4.2.1 Phase I market, 2018 - 2030 (USD Million)
  • 4.3 Phase II
    • 4.3.1 Phase II market, 2018 - 2030 (USD Million)
  • 4.4 Phase III
    • 4.4.1 Phase III market, 2018 - 2030 (USD Million)
  • 4.5 Phase IV
    • 4.5.1 Phase IV market, 2018 - 2030 (USD Million)

Chapter 5 U.S. Clinical Trials Market: Study Design Segment Analysis

  • 5.1 U.S. Clinical Trials: Market Share Analysis, 2021 & 2030
  • 5.2 Interventional Studies
    • 5.2.1 Interventional market, 2018 - 2030 (USD Million)
  • 5.3 Observational Studies
    • 5.3.1 Observational studies market, 2018 - 2030 (USD Million)
  • 5.4 Expanded Access Studies
    • 5.4.1 Expanded access studies market, 2018 - 2030 (USD Million)

Chapter 6 U.S. Clinical Trials Market: Indication Segment Analysis

  • 6.1 U.S. Clinical Trials: Market Share Analysis, 2021 & 2030
  • 6.2 Autoimmune/Inflammation
    • 6.2.1 Autoimmune/inflammation market, 2018 - 2030 (USD Million)
    • 6.2.2 Rheumatoid Arthritis
      • 6.2.2.1 Rheumatoid arthritis market, 2018 - 2030 (USD Million)
    • 6.2.3 Multiple Sclerosis (MS)
      • 6.2.3.1 Multiple sclerosis market, 2018 - 2030 (USD Million)
    • 6.2.4 Osteoarthritis
      • 6.2.4.1 Osteoarthritis market, 2018 - 2030 (USD Million)
    • 6.2.5 Irritable Bowel Syndrome (IBS)
      • 6.2.5.1 Irritable Bowel Syndrome (IBS) market, 2018 - 2030 (USD Million)
    • 6.2.6 Others
      • 6.2.6.1 Others market, 2018 - 2030 (USD Million)
  • 6.3 Pain Management
    • 6.3.1 Pain management market, 2018 - 2030 (USD Million)
    • 6.3.2 Chronic pain
      • 6.3.2.1 Chronic pain market, 2018 - 2030 (USD Million)
    • 6.3.3 Acute pain
      • 6.3.3.1 Acute pain market, 2018 - 2030 (USD Million)
  • 6.4 Oncology
    • 6.4.1 Oncology market, 2018 - 2030 (USD Million)
    • 6.4.2 Blood cancer
      • 6.4.2.1 Blood cancer market, 2018 - 2030 (USD Million)
    • 6.4.3 Solid tumors
      • 6.4.3.1 Solid tumors market, 2018 - 2030 (USD Million)
    • 6.4.4 Others
      • 6.4.4.1 Others market, 2018 - 2030 (USD Million)
  • 6.5 CNS Conditions
    • 6.5.1 CNS conditions market, 2018 - 2030 (USD Million)
    • 6.5.2 Epilepsy
      • 6.5.2.1 Epilepsy market, 2018 - 2030 (USD Million)
    • 6.5.3 Parkinson's disease (PD)
      • 6.5.3.1 Parkinson's disease (PD) market, 2018 - 2030 (USD Million)
    • 6.5.4 Huntington's disease
      • 6.5.4.1 Huntington's disease market, 2018 - 2030 (USD Million)
    • 6.5.5 Stroke
      • 6.5.5.1 Stroke market, 2018 - 2030 (USD Million)
    • 6.5.6 Traumatic Brain Injury (TBI)
      • 6.5.6.1 Traumatic Brain Injury (TBI) market, 2018 - 2030 (USD Million)
    • 6.5.7 Amyotrophic Lateral Sclerosis (ALS)
      • 6.5.7.1 Amyotrophic Lateral Sclerosis (ALS) market, 2018 - 2030 (USD Million)
    • 6.5.8 Muscle Regeneration
      • 6.5.8.1 Muscle Regeneration market, 2018 - 2030 (USD Million)
    • 6.5.9 Others
      • 6.5.9.1 Others market, 2018 - 2030 (USD Million)
  • 6.6 Diabetes
    • 6.6.1 Diabetes market, 2018 - 2030 (USD Million)
  • 6.7 Obesity
    • 6.7.1 Obesity market, 2018 - 2030 (USD Million)
  • 6.8 Cardiovascular
    • 6.8.1 Cardiovascular market, 2018 - 2030 (USD Million)
  • 6.9 Other Indications
    • 6.9.1 Other indications market, 2018 - 2030 (USD Million)

Chapter 7 U.S. Clinical Trials Indication Outlook, by Study Design, Criss-Cross Analysis

  • 7.1 U.S. autoimmune/inflammation clinical trials market, by study design, 2018 - 2030 (USD Million)
    • 7.1.1 Interventional studies
      • 7.1.1.1 Interventional studies market, 2018 - 2030 (USD Million)
    • 7.1.2 Observational Studies
      • 7.1.2.1 Observational studies market, 2018 - 2030 (USD Million)
    • 7.1.3 Expanded access
      • 7.1.3.1 Expanded access market, 2018 - 2030 (USD Million)
  • 7.2 U.S. pain management clinical trials market, by study design, 2018 - 2030 (USD Million)
    • 7.2.1 Interventional studies
      • 7.2.1.1 Interventional studies market, 2018 - 2030 (USD Million)
    • 7.2.2 Observational studies
      • 7.2.2.1 Observational studies market, 2018 - 2030 (USD Million)
    • 7.2.3 Expanded access
      • 7.2.3.1 Expanded access market, 2018 - 2030 (USD Million)
  • 7.3 U.S. Oncology clinical trials market, by study design, 2018 - 2030 (USD Million)
    • 7.3.1 Interventional studies
      • 7.3.1.1 Interventional studies market, 2018 - 2030 (USD Million)
    • 7.3.2 Observational studies
      • 7.3.2.1 Observational studies market, 2018 - 2030 (USD Million)
    • 7.3.3 Expanded access
      • 7.3.3.1 Expanded access market, 2018 - 2030 (USD Million)
  • 7.4 U.S. CNS condition clinical trials market, by study design, 2018 - 2030 (USD Million)
    • 7.4.1 Interventional studies
      • 7.4.1.1 Interventional studies market, 2018 - 2030 (USD Million)
    • 7.4.2 Observational studies
      • 7.4.2.1 Observational studies market, 2018 - 2030 (USD Million)
    • 7.4.3 Expanded access
      • 7.4.3.1 Expanded access market, 2018 - 2030 (USD Million)
  • 7.5 U.S. diabetes clinical trials market, by study design, 2018 - 2030 (USD Million)
    • 7.5.1 Interventional studies
      • 7.5.1.1 Interventional studies market, 2018 - 2030 (USD Million)
    • 7.5.2 Observational studies
      • 7.5.2.1 Observational studies market, 2018 - 2030 (USD Million)
    • 7.5.3 Expanded access
      • 7.5.3.1 Expanded access market, 2018 - 2030 (USD Million)
  • 7.6 U.S. obesity clinical trials market, by study design, 2018 - 2030 (USD Million)
    • 7.6.1 Interventional studies
      • 7.6.1.1 Interventional studies market, 2018 - 2030 (USD Million)
    • 7.6.2 Observational studies
      • 7.6.2.1 Observational studies market, 2018 - 2030 (USD Million)
    • 7.6.3 Expanded access
      • 7.6.3.1 Expanded access market, 2018 - 2030 (USD Million)
  • 7.7 U.S. cardiovascular clinical trials market, by study design, 2018 - 2030 (USD Million)
    • 7.7.1 Interventional studies
      • 7.7.1.1 Interventional studies market, 2018 - 2030 (USD Million)
    • 7.7.2 Observational Studies
      • 7.7.2.1 Observational studies market, 2018 - 2030 (USD Million)
    • 7.7.3 Expanded access
      • 7.7.3.1 Expanded access market, 2018 - 2030 (USD Million)
  • 7.8 U.S. others clinical trials market, by study design, 2018 - 2030 (USD Million)
    • 7.8.1 Interventional studies
      • 7.8.1.1 Interventional studies market, 2018 - 2030 (USD Million)
    • 7.8.2 Observational Studies
      • 7.8.2.1 Observational studies market, 2018 - 2030 (USD Million)
    • 7.8.3 Expanded access
      • 7.8.3.1 Expanded access market, 2018 - 2030 (USD Million)

Chapter 8 Company Profiles

  • 8.1 Company Profiles
    • 8.1.1 IQVIA Holdings Inc.
      • 8.1.1.1 Company overview
      • 8.1.1.2 Financial performance
      • 8.1.1.3 Service benchmarking
      • 8.1.1.4 Strategic initiatives
    • 8.1.2 PAREXEL International Corporation
      • 8.1.2.1 Company overview
      • 8.1.2.2 Service benchmarking
      • 8.1.2.3 Strategic initiatives
    • 8.1.3 Thermo Fisher Scientific (Pharmaceutical Product Development)
      • 8.1.3.1 Company overview
      • 8.1.3.2 Service benchmarking
      • 8.1.3.3 Strategic initiatives
    • 8.1.4 Charles River Laboratory
      • 8.1.4.1 Company overview
      • 8.1.4.2 Financial performance
      • 8.1.4.3 Service benchmarking
      • 8.1.4.4 Strategic initiatives
    • 8.1.5 ICON plc
      • 8.1.5.1 Company overview
      • 8.1.5.2 Financial performance
      • 8.1.5.3 Service benchmarking
      • 8.1.5.4 Strategic initiatives
    • 8.1.6 LabCorp
      • 8.1.6.1 Company overview
      • 8.1.6.2 Financial performance
      • 8.1.6.3 Service benchmarking
      • 8.1.6.4 Strategic initiatives
    • 8.1.7 Syneos Health Inc.
      • 8.1.7.1 Company overview
      • 8.1.7.2 Financial performance
      • 8.1.7.3 Service benchmarking
      • 8.1.7.4 Strategic initiatives
    • 8.1.8 SGS SA
      • 8.1.8.1 Company overview
      • 8.1.8.2 Financial performance
      • 8.1.8.3 Service benchmarking
      • 8.1.8.4 Strategic initiatives
    • 8.1.9 Wuxi AppTec
      • 8.1.9.1 Company overview
      • 8.1.9.2 Financial performance
      • 8.1.9.3 Service benchmarking
      • 8.1.9.4 Strategic initiatives
    • 8.1.10 Eli Lilly and Company
      • 8.1.10.1 Company overview
      • 8.1.10.2 Financial performance
      • 8.1.10.3 Service benchmarking
    • 8.1.11 Novo Nordisk A/S
      • 8.1.11.1 Company overview
      • 8.1.11.2 Financial performance
      • 8.1.11.3 Service benchmarking
    • 8.1.12 Pfizer Inc.
      • 8.1.12.1 Company overview
      • 8.1.12.2 Financial performance
      • 8.1.12.3 Service benchmarking
      • 8.1.12.4 Strategic initiatives
    • 8.1.13 Covance Inc.
      • 8.1.13.1 Company overview
      • 8.1.13.2 Financial performance
      • 8.1.13.3 Service benchmarking

List of Tables

  • Table 1 U.S. clinical trials market, by phase, 2018 - 2030 (USD Million)
  • Table 2 U.S. clinical trials market, by study design, 2018 - 2030 (USD Million)
  • Table 3 U.S. clinical trials market, by indication, 2018 - 2030 (USD Million)
  • Table 4 U.S. autoimmune/inflammation clinical trials market, by indication, 2018 - 2030 (USD Million)
  • Table 5 U.S. pain management clinical trials market, by indication, 2018 - 2030 (USD Million)
  • Table 6 U.S. oncology clinical trials market, by indication, 2018 - 2030 (USD Million)
  • Table 7 U.S. CNS conditions clinical trials market, by indication, 2018 - 2030 (USD Million)
  • Table 8 U.S. autoimmune/inflammation clinical trials market, by study design, 2018 - 2030 (USD Million)
  • Table 9 U.S. pain management clinical trials market, by study design, 2018 - 2030 (USD Million)
  • Table 10 U.S. oncology clinical trials market, by study design, 2018 - 2030 (USD Million)
  • Table 11 U.S. CNS condition clinical trials market, by study design, 2018 - 2030 (USD Million)
  • Table 12 U.S. diabetes clinical trials market, by study design, 2018 - 2030 (USD Million)
  • Table 13 U.S. obesity clinical trials market, by study design, 2018 - 2030 (USD Million)
  • Table 14 U.S. cardiovascular clinical trials market, by study design, 2018 - 2030 (USD Million)
  • Table 15 U.S. others clinical trials market, by study design, 2018 - 2030 (USD Million)

List of Figures

  • Fig. 1 Market research process
  • Fig. 2 Information procurement
  • Fig. 3 Primary research pattern
  • Fig. 4 Market research approaches
  • Fig. 5 QFD modeling for market share assessment
  • Fig. 6 Market formulation & validation
  • Fig. 7 Commodity flow analysis
  • Fig. 8 Volume price analysis
  • Fig. 9 U.S. Clinical trials market snapshot (2021)
  • Fig. 10 U.S. clinical trials market segmentation
  • Fig. 11 U.S. clinical trials market: Strategy framework
  • Fig. 12 Parent market outlook
  • Fig. 13 Related/ancillary market outlook
  • Fig. 14 Penetration & growth prospect mapping
  • Fig. 15 Virtual clinical trials
  • Fig. 16 Companies with affected trials, by size
  • Fig. 17 Affected trials, by study phase
  • Fig. 18 Market driver relevance analysis (Current & future impact)
  • Fig. 19 Market restraint relevance analysis (Current & future impact)
  • Fig. 20 Porter's five forces analysis
  • Fig. 21 SWOT analysis, by factor (political & legal, economic and technological)
  • Fig. 22 U.S. clinical trials market phase outlook: Segment dashboard
  • Fig. 23 U.S. clinical trials market: Phase movement analysis
  • Fig. 24 Phase I market, 2018 - 2030 (USD Million)
  • Fig. 25 Phase II market, 2018 - 2030 (USD Million)
  • Fig. 26 Phase III market, 2018 - 2030 (USD Million)
  • Fig. 27 Phase IV market, 2018 - 2030 (USD Million)
  • Fig. 28 U.S. clinical trials market study design outlook: Segment dashboard
  • Fig. 29 U.S. clinical trials market: Study design movement analysis
  • Fig. 30 Interventional studies market, 2018 - 2030 (USD Million)
  • Fig. 31 Observational studies market, 2018 - 2030 (USD Million)
  • Fig. 32 Expanded access studies market, 2018 - 2030 (USD Million)
  • Fig. 33 U.S. clinical trials market indication outlook: Segment dashboard
  • Fig. 34 U.S. clinical trials market: Indication movement analysis
  • Fig. 35 Autoimmune/inflammation market, 2018 - 2030 (USD Million)
  • Fig. 36 Rheumatoid arthritis clinical trial by phase (%)
  • Fig. 37 Rheumatoid arthritis market, 2018 - 2030 (USD Million)
  • Fig. 38 Multiple sclerosis clinical trial by phase (%)
  • Fig. 39 Multiple sclerosis market, 2018 - 2030 (USD Million)
  • Fig. 40 Osteoarthritis clinical trials by phase (%)
  • Fig. 41 Osteoarthritis market, 2018 - 2030 (USD Million)
  • Fig. 42 Irritable bowel syndrome clinical trials by phase (%)
  • Fig. 43 Irritable Bowel Syndrome (IBS) market, 2018 - 2030 (USD Million)
  • Fig. 44 Others market, 2018 - 2030 (USD Million)
  • Fig. 45 Pain management market, 2018 - 2030 (USD Million)
  • Fig. 46 Chronic pain clinical trial by phase (%)
  • Fig. 47 Chronic pain market, 2018 - 2030 (USD Million)
  • Fig. 48 Acute pain clinical trial by phase (%)
  • Fig. 49 Acute pain market, 2018 - 2030 (USD Million)
  • Fig. 50 Oncology market, 2018 - 2030 (USD Million)
  • Fig. 51 Blood cancer market, 2018 - 2030 (USD Million)
  • Fig. 52 Solid tumors market, 2018 - 2030 (USD Million)
  • Fig. 53 Others market, 2018 - 2030 (USD Million)
  • Fig. 54 CNS conditions market, 2018 - 2030 (USD Million)
  • Fig. 55 Epilepsy market, 2018 - 2030 (USD Million)
  • Fig. 56 Parkinson's disease (PD) market, 2018 - 2030 (USD Million)
  • Fig. 57 Huntington's disease market, 2018 - 2030 (USD Million)
  • Fig. 58 Stroke market, 2018 - 2030 (USD Million)
  • Fig. 59 Traumatic Brain Injury (TBI) market, 2018 - 2030 (USD Million)
  • Fig. 60 Amyotrophic lateral sclerosis (ALS) market, 2018 - 2030 (USD Million)
  • Fig. 61 Muscle regeneration market, 2018 - 2030 (USD Million
  • Fig. 62 Others market, 2018 - 2030 (USD Million)
  • Fig. 63 Diabetes market, 2018 - 2030 (USD Million)
  • Fig. 64 Obesity clinical trial by phase (%)
  • Fig. 65 Obesity market, 2018 - 2030 (USD Million)
  • Fig. 66 Cardiovascular market, 2018 - 2030 (USD Million)
  • Fig. 67 Others indications market, 2018 - 2030 (USD Million)
  • Fig. 68 Interventional studies market, 2018 - 2030 (USD Million)
  • Fig. 69 Observational studies market, 2018 - 2030 (USD Million)
  • Fig. 70 Expanded access market, 2018 - 2030 (USD Million)
  • Fig. 71 Interventional studies market, 2018 - 2030 (USD Million)
  • Fig. 72 Observational studies market, 2018 - 2030 (USD Million)
  • Fig. 73 Expanded access market, 2018 - 2030 (USD Million)
  • Fig. 74 Interventional studies market, 2018 - 2030 (USD Million)
  • Fig. 75 Observational studies market, 2018 - 2030 (USD Million)
  • Fig. 76 Expanded access market, 2018 - 2030 (USD Million)
  • Fig. 77 Interventional studies market, 2018 - 2030 (USD Million)
  • Fig. 78 Observational studies market, 2018 - 2030 (USD Million)
  • Fig. 79 Expanded access market, 2018 - 2030 (USD Million)
  • Fig. 80 Interventional studies market, 2018 - 2030 (USD Million)
  • Fig. 81 Observational studies market, 2018 - 2030 (USD Million)
  • Fig. 82 Expanded access market, 2018 - 2030 (USD Million)
  • Fig. 83 Interventional studies market, 2018 - 2030 (USD Million)
  • Fig. 84 Observational studies market, 2018 - 2030 (USD Million)
  • Fig. 85 Expanded access market, 2018 - 2030 (USD Million)
  • Fig. 86 Interventional studies market, 2018 - 2030 (USD Million)
  • Fig. 87 Observational studies market, 2018 - 2030 (USD Million)
  • Fig. 88 Expanded access market, 2018 - 2030 (USD Million)
  • Fig. 89 Interventional studies market, 2018 - 2030 (USD Million)
  • Fig. 90 Observational studies market, 2018 - 2030 (USD Million)
  • Fig. 91 Expanded access market, 2018 - 2030 (USD Million)